Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 47Carcinoma, Non-Small-Cell Lung 30Pancreatic Neoplasms 24Ovarian Neoplasms 23Fallopian Tube Neoplasms 21Triple Negative Breast Neoplasms 15Breast Neoplasms, Male 14Brenner Tumor 12Melanoma 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Lung Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma of Lung 7Urinary Bladder Neoplasms 6Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Stomach Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Cholangiocarcinoma 4Pleural Effusion, Malignant 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Transitional Cell 3Uveal Melanoma 2Tongue Neoplasms 2Thymoma 2

Interventions

Radiotherapy 2Bronchoscopy 2X-Rays 1Taxes 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hemoptysis × Taxes × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡